GSKGlaxoSmithKlineRunning, no new patients
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
Lung Cancer, Non-Small Cell
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 758 (final count)
- Started
- Dec 8, 2020
- Main results expected
- Jun 5, 2025
- Fully finished
- Mar 30, 2027
- Results posted
- Jul 1, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS) (Arm A Versus Arm C)
Measured over: Up to approximately 234 weeks
Overall Survival (OS) (Arm B Versus Arm C)
Measured over: Up to approximately 234 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04655976 · record last updated 2026-07-01 · checked 2026-11-09 15:47 UTC